GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-25 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
In February 2025, the firm announced a historic multi-year renewal of its long-term partnership with the Ultimate Fighting Championship, marking the largest sponsorship deal in the history of both companies. Several UFC champions have partnered with Monster Energy, including Conor McGregor, Justin Gaethje, Cain Velasquez, and Jon "Bones" Jones. In November 2012, the firm announced a long-term partnership with the Professional Bull Riders, and currently sponsors several riders including Jose Vitor Leme, Cody Teel, and Derek Kolbaba. Starting in 2018, they became the title sponsor of the PBR's premiership tour, known as the Unleash the Beast tour.
=== Dicamba lawsuit === On 27 January 2020, the first-ever lawsuit concerning Dicamba-related products began in Cape Girardeau, Missouri. The lawsuit involved a peach farmer who alleged that Dicamba-based herbicides caused significant damage to his crops and trees. It had also been filed in November 2016, when Dicamba was still owned by Monsanto. On 14 February 2020, the jury involved in the lawsuit ruled against BASF and its co-defendant Bayer, which had acquired Monsanto and its products, and found in favor of the peach grower, Bader Farms owner Bill Bader. BASF and Bayer were also ordered to pay Bader $15 million in damages. On 15 February 2020, Monsanto and BASF were ordered to pay an additional $250 million in punitive damages.
The active chemical in pennyroyal is pulegone. Pulegone is a ketone and on the cellular level, ketones can act as enzyme inhibitors. The carbonyl center of the pulegone structure acts as a strong electrophile, causing active sites on enzymes to bind with pulegone instead of the target protein. The exocyclic double bond found in pulegone is vital to the activation and binding mechanism of the molecule and causes it to be an effective hepatotoxin. When ingested, pulegone targets the liver and kidneys, among other organs. Studies conducted on rats show that one of the main effects is the inhibition of contractile activity in the myometrium and death by kidney failure. The studies also found that long-term exposure to pennyroyal increased incidences of urinary bladder tumors.
=== UNGASS guidance === Three Special Session of the United Nations General Assembly (UNGASS) sessions have been held on the subject of drugs: "Drug abuse" (1990), "World drug problem" (1998), and "World drug problem" (2016). These high-level gatherings, involving heads of state and ministers, are documented usually in the form of a political declaration, an action plan, or a strategy that provide additional treaty guidance. These sessions can indicate whether the status quo will be maintained or if there is a broad openness to reform. In March 2016, the INCB stated that the UN drug treaties do not mandate a "war on drugs" and that the choice is not between "'militarized' drug law enforcement on one hand and the legalization of non-medical use of drugs on the other", health and welfare should be the focus of drug policy. That April, at the UNGASS on the "World drug problem", the Wall Street Journal assessed the attendees' positions as "somewhat" in two camps: "Some European and South American countries as well as the U.S. favored softer approaches.
Sources: en.wikipedia.org
Blood dyscrasias (abnormalities in the cell composition of blood), such as: Agranulocytosis – a drop in white blood cell counts that leaves one open to potentially life-threatening infections Neutropenia – a drop in the number of neutrophils (white blood cells that specifically fight bacteria) in one's blood Leucopenia – a less severe drop in white blood cell counts than agranulocytosis Thrombocytopenia – a drop in the number of platelets in the blood. Platelets are responsible for blood clotting and hence this leads to an increased risk of bruising and other bleeds Neuroleptic malignant syndrome – a potentially fatal condition that appear to result from central D2 receptor blockade. The symptoms include: Hyperthermia Muscle rigidity Rhabdomyolysis Autonomic instability (e.g., tachycardia, diarrhea, diaphoresis, etc.) Mental status changes (e.g., coma, agitation, anxiety, confusion, etc.) Unknown incidence adverse effects include
=== Extrapulmonary localized in the lymph nodes === This is an extremely rare type of small cell, and there has been little information in the scientific community. It appears to occur in only one or more lymph nodes, and nowhere else in the body. Treatment is similar to small-cell lung cancer, but survival rates are much higher than other small-cell carcinomas.
Representative Don Bacon became the first Republican House member to urge that Hegseth be fired. At least five political appointees within the Department of Defense resigned by April 24. That day, Joe Kesper, Hegseth's chief of staff, resigned, but stated that he would remain at the department as a special government employee. The firings and resignations led to a crisis within the Department of Defense that was described as a "free-for-all" by one employee who spoke to Politico.
Sources: en.wikipedia.org
Complementary to the field of structural genomics, protein structure prediction develops efficient mathematical models of proteins to computationally predict the molecular formations in theory, instead of detecting structures with laboratory observation. The most successful type of structure prediction, known as homology modeling, relies on the existence of a "template" structure with sequence similarity to the protein being modeled; structural genomics' goal is to provide sufficient representation in solved structures to model most of those that remain. Although producing accurate models remains a challenge when only distantly related template structures are available, it has been suggested that sequence alignment is the bottleneck in this process, as quite accurate models can be produced if a "perfect" sequence alignment is known. Many structure prediction methods have served to inform the emerging field of protein engineering, in which novel protein folds have already been designed. Many proteins (in eukaryotes ~33%) contain large unstructured but biologically functional segments and can be classified as intrinsically disordered proteins. Predicting and analysing protein disorder is an important part of protein structure characterisation.
=== Allegations of illegal marketing === In 2004, separate civil suits alleging illegal marketing of citalopram and escitalopram for use by children and teenagers by Forest were initiated by two whistleblowers: a physician named Joseph Piacentile and a Forest salesman named Christopher Gobble. In February 2009, the suits were joined. Eleven states and the District of Columbia filed notices of intent to intervene as plaintiffs in the action. The suits alleged that Forest illegally engaged in off-label promotion of Lexapro for use in children; hid the results of a study showing lack of effectiveness in children; paid kickbacks to physicians to induce them to prescribe Lexapro to children; and conducted so-called "seeding studies" that were, in reality, marketing efforts to promote the drug's use by doctors. Forest denied the allegations but ultimately agreed to settle with the plaintiffs for over $313 million.
Brazilian topography is diverse, encompassing hills, mountains, plains, highlands, and scrublands. Nearly half of its territory lies below 200 meters, and barely 7% is above 800 meters. The main upland area occupies most of the southern half of the country. The northwestern parts of the plateau consist of broad, rolling terrain broken by low, rounded hills. The southeastern section is more rugged, with a complex mass of ridges and mountain ranges reaching elevations of up to 1,200 meters (3,900 ft). These ranges include the Mantiqueira and Espinhaço mountains and the Serra do Mar. In the north, the Guiana Highlands form a major drainage divide, separating rivers that flow south into the Amazon Basin from rivers that empty into the Orinoco River system, in Venezuela, to the north. The highest point in Brazil is the Pico da Neblina at 2,994 meters (9,823 ft), and the lowest is the Atlantic Ocean. Brazil has a dense and complex system of rivers, one of the world's most extensive, with eight major drainage basins, all of which drain into the Atlantic. Major rivers include the Amazon (the world's largest in terms of water volume), the Paraná and its major tributary the Iguaçu (which includes the Iguazu Falls), the Negro, São Francisco, Xingu, Madeira and Tapajós rivers.
For some polyprotic acids, dissociation (or association) occurs at more than one nonequivalent site, and the observed macroscopic equilibrium constant, or macro-constant, is a combination of micro-constants involving distinct species. When one reactant forms two products in parallel, the macro-constant is a sum of two micro-constants,
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.